Oxford spin-out OMass Therapeutics lands €275 million to bring novel small-molecule therapies closer to patients

In breve · dalla fonte (EU-Startups)

Di cosa si tratta

OMass Therapeutics, a UK BioTech company developing small molecule therapeutics against highly validated target ecosystems, announced an oversubscribed €275 million (£230 million) Series C round. The round was co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with additional participation from Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences. Each […] The post Oxford spin-out OMass Therapeutics lands €275 million to bring novel small-molecule therapies closer to patients appeared first on EU-Startups .

Anteprima pubblicata dalla testata nel proprio feed. DuoBiz non ripubblica l'articolo né le immagini: per il testo completo, i dati e le dichiarazioni vai alla fonte.